
|Videos|August 8, 2018
Dr. Ai on the FDA Approval of Mogamulizumab in CTCL
Author(s)Wei Z. Ai, MD
Wei Z. Ai, MD, hematologist, University of California, San Francisco, discusses the FDA approval of mogamulizumab for the treatment of patients with cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy.
Advertisement
Wei Z. Ai, MD, hematologist, University of California, San Francisco, discusses the FDA approval of mogamulizumab for the treatment of patients with cutaneous T-cell lymphoma who have received at least 1 prior systemic therapy.
Advertisement
Advertisement
Advertisement






















